Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis

References

• Scott DL. Early rheumatoid arthritis. Br Med Bull. 2007;81-82:97–114.
   PubMed Web of Science ®Google Scholar
• National Clinical Centre for Chronic Conditions. Clinical guidelines. Rheumatoid arthritis: national clinical guideline for management and treatment in adults. London: Royal College of Physicians (UK); 2018.
   Google Scholar
• Singh JA, Hossain A, Mudano AS, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;5:CD012657.
   PubMedGoogle Scholar
• van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–870.
   PubMed Web of Science ®Google Scholar
• Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheum Dis. 2015;74(5):793–794.
   PubMed Web of Science ®Google Scholar
• Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17(181).
   PubMedGoogle Scholar
• Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis. 2004;63(2):149–155.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375–382.
   PubMed Web of Science ®Google Scholar
• Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis. 2012;71(6):989–992.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443–1450.
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75–85.
   PubMed Web of Science ®Google Scholar
• Nam JL, Villeneuve E, Hensor EM, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis. 2014;73(6):1027–1036.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383(9914):321–332.
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–3443.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016 [cited 2018 Oct 11]. Available from: https://www.nice.org.uk/guidance/ta375/documents/rheumatoid-arthritis-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumab-review-id537-appraisal-consultation-document2
   Google Scholar
• Cai W, Gu Y, Cui H, et al. The efficacy and safety of mainstream medications for patients with cDMARD-naive rheumatoid arthritis: a network meta-analysis. Front Pharmacol. 2018;9:138.
   PubMed Web of Science ®Google Scholar
• Albert DA. Are all biologics the same? Optimal treatment strategies for patients with early rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. J Clin Rheumatol. 2015;21(8):398–404.
   PubMed Web of Science ®Google Scholar
• Donahue KE, Gartlehner G, Schulman ER, et al. Drug therapy for early rheumatoid arthritis: A systematic review update. 2018 [cited 2018 Nov 29]. Available from: https://effectivehealthcare.ahrq.gov/topics/rheumatoid-arthritis-medicine-update/final-report-update-2018
   Google Scholar
• van der Velde G, Pham B, Machado M, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2011;63(1):65–78.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilars Initiative. Huge discount on biosimilar infliximab in Norway. 2015 [updated 2015 Mar 13; cited 2018 Oct 16]. Available from: http://www.gabionline.net/Biosimilars/General/Huge-discount-on-biosimilar-infliximab-in-Norway
   Google Scholar
• Kim J, Hong J, Kudrin A 5 Year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. American College of Rheumatology Annual Meeting; 2014; Boston, Massachusetts.
   Google Scholar
• Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65–S71.
   PubMed Web of Science ®Google Scholar
• Jha A, Upton A, Dunlop WC, et al. The budget impact of biosimilar infliximab (Remsima(R)) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. [cited 2018 Oct 25]. Available from: http://handbook.cochrane.org.
   Google Scholar
• clinicaltrials.gov. NCT00480272 - Prospective study on intensive early rheumatoid arthritis treatment with adalimumab: induction of remission and maintenance - ’CURE’ A phase IV multicenter, randomized, double-blind study; 2017. [cited 2018 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT00480272
   Google Scholar
• Hochberg MC, Silman AJ, Smolen JS, et al. Rheumatology E-Book. Philadelphia: Elsevier Health Sciences; 2018.
   Google Scholar
• Wood L Global clinical insight on 17 biosimilar versions of Remicade (infliximab) drug in clinical pipeline 2016 - Research and markets. PR Newswire; 2016 [cited 2016 Oct 19]. Available from: https://www.prnewswire.com/news-releases/global-clinical-insight-on-17-biosimilar-versions-of-remicade-infliximab-drug-in-clinical-pipeline-2016—research-and-markets-300347760.html
   Google Scholar
• White I. Network meta-analysis. In: editors, Palmer TM, Jonathan AC. Meta-analysis in stata: an updated collection from the stata journal. 2nd ed. College Staton, Texas: Stata Press; 2015:410–450
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(3):716–722.
   PubMedGoogle Scholar
• Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68(6):823–827.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–3390.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406–415.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70(6):1039–1046.
   PubMed Web of Science ®Google Scholar
• Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl. 2007;80:25–33.
   PubMedGoogle Scholar
• Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol. 2006;24(6 Suppl 43):S77–S82.
   Web of Science ®Google Scholar
• Allaart CF, Markusse IM, Lems WF. What have we learned from BeSt? Clin Immunol. 2018;186:74–78.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis. 2007;66(9):1227–1232.
   PubMed Web of Science ®Google Scholar
• Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):823–828.
   PubMed Web of Science ®Google Scholar
• Markusse IM, Akdemir G, Dirven L, et al. Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial. Ann Intern Med. 2016;164(8):523–531.
   PubMed Web of Science ®Google Scholar
• van Den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S35–S38.
   PubMed Web of Science ®Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2007;56(7):2129–2134.
   PubMedGoogle Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61(1):4–12.
   PubMed Web of Science ®Google Scholar
• van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis. 2009;68(7):1153–1158.
   PubMed Web of Science ®Google Scholar
• Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69(7):1333–1337.
   PubMed Web of Science ®Google Scholar
• van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68(6):914–921.
   PubMed Web of Science ®Google Scholar
• Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56(12):3919–3927.
   PubMedGoogle Scholar
• Rantalaiho V, Kautiainen H, Korpela M, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximabThe 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Ann Rheum Dis. 2014;73(11):1954–1961.
   PubMed Web of Science ®Google Scholar
• Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis. 2013;72(6):851–857.
   PubMed Web of Science ®Google Scholar
• Kuusalo L, Puolakka K, Kautiainen H, et al. High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis. Clin Rheumatol. 2018;37(6):1689–1694.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27–35.
   PubMed Web of Science ®Google Scholar
• Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology (Oxford). 2010;49(10):1971–1974.
   PubMed Web of Science ®Google Scholar
• Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2009;68(12):1898–1901.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272–2283.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Doyle MK, et al. Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care Res (Hoboken). 2013;65(11):1732–1742.
   PubMed Web of Science ®Google Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. PharmacoEconomics. 2006;24(12):1221–1232.
   PubMed Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii–iv, xi–xiii, 1–229.
   PubMed Web of Science ®Google Scholar
• Davies A, Cifaldi MA, Segurado OG, et al. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol. 2009;36(1):16–26.
   PubMed Web of Science ®Google Scholar
• van Den Hout WB, Goekoop-Ruiterman YP, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2009;61(3):291–299.
   PubMedGoogle Scholar
• Spinelli FR, Valesini G. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol. 2013;31(6):954–963.
   PubMed Web of Science ®Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1–610.
   Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581.
   PubMed Web of Science ®Google Scholar
• Corker E, Henderson RC, Lempp H, et al. Internalised stigma in people with rheumatoid arthritis: a cross sectional study to establish the psychometric properties of the ISMI-RA. BMC Musculoskelet Disord. 2016;17:244.
   PubMed Web of Science ®Google Scholar
• Pentek M, Gulacsi L, Rojkovich B, et al. Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. Eur J Health Econ. 2014;15(Suppl 1):S83–S92.
   PubMedGoogle Scholar
• Pentek M, Rojkovich B, Czirjak L, et al. Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective. Eur J Health Econ. 2014;15(Suppl 1):S73–S82.
   PubMedGoogle Scholar
• Mitchell PM, Venkatapuram S, Richardson J, et al. Are quality-adjusted life years a good proxy measure of individual capabilities? PharmacoEconomics. 2017;35(6):637–646.
   PubMed Web of Science ®Google Scholar
• Tang K, Beaton DE, A B, et al. Measures of work disability and productivity: rheumatoid arthritis specific work productivity survey (WPS-RA), workplace activity limitations scale (WALS), work instability scale for rheumatoid arthritis (RA-WIS), work limitations questionnaire (WLQ), and work productivity and activity impairment questionnaire (WPAI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S337–S349.
   PubMed Web of Science ®Google Scholar
• Jalal H, O’Dell JR, Bridges SL Jr., et al. Cost-effectiveness of triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(12):1751–1757.
   PubMed Web of Science ®Google Scholar
• Han S, Kim S, Kim J, et al. The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016. J Crohns Colitis. 2017;11(Issue suppl_1):S377.
   Google Scholar